You are here: Industry Insights > psoriasis drug

News List

MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US b3cnewswire
August 26, 2020
MC2 Therapeutics retains full ownership of WYNZORA Cream under the Collaboration Agreement and MC2 Therapeutics and EPI Health will utilize their combined resources to make WYNZORA Cream a leading patient preferred topical treatment of psoriasis in the US
Focusing on Interior and Exterior: the Chinese Psoriasis Drug Market to Usher in a Great Change Miling
October 25, 2019
Eli Lilly announced on Sep. 4 that its new psoriasis drug: ixekizumab (Taltz®) had entered China and passed the marketing approval of the NMPA, which is another blockbuster psoriasis drug approved following the approval of the “first-in-class” new drug be
New psoriasis drug study yields positive results: Dr Reddy’s expressbpd
June 14, 2019
According to a press release from the city-based drug-maker, the detailed safety and efficacy data from the study would be presented in future dermatology conferences
Boehringer pins hopes on novel psoriasis drug pharmaphorum
April 28, 2018
Boehringer Ingelheim has announced bold plans to bring a generation of new medicines to market in the coming years.
Sun Pharma signs $55m manufacturing deal for investigational psoriasis drug pharmafile
July 05, 2017
India’s biggest pharma firm has signed a $55 million long-term manufacturing deal with Korea’s Samsung BioLogics for Tildrakizumab, an investigational IL-23p19 inhibitor currently being assessed for efficacy in treating moderate to severe plaque psoriasis
FDA approves new psoriasis drug that induced suicide in trial europeanpharmaceuticalreview
February 20, 2017
The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection.